Zoom conference call scheduled for 9:00 AM ET
REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024.
Later that day, Company management, will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_K5GBuG1FQ7Srbe_UJ7r2iQ
The entire conference will be available online on the company’s website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
For more information, please visit: www.evogene.com.
Contacts
ir@evogene.com
Tel: +972-8-9311901
Logo – https://healthtechnologynet.com/wp-content/uploads/2024/08/Evogene_Logo.jpg
SOURCE Evogene
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…